Abstract: A method of detecting the presence of Neisseria gonorrhoeae in a sample. The method involves detecting a first target sequence taken from the NGO1642 gene and/or a second target sequence taken from the NGO1012 gene. The method may involve a step of amplifying the target sequence, and may involve hybridising the target sequence to a nucleic acid probe and identifying hybridisation. The method may involve simultaneous detection of other target sequences, e.g. from other pathogens.

Abstract: The present invention provides compositions and method for treating a subject having or suspected of having pulmonary dysfunction resulting from impaired alveolar macrophage (AM) development. The compositions comprise granulocyte-macrophage colony stimulating factor (GM-CSF) in formulations suitable for pulmonary airway administration.

Abstract: An immune enhancer comprising at least an interferon and a granulocyte-macrophage colony-stimulating factor, and an immunotherapeutic phar-maceutical composition comprising at least an antigen and the above-mentioned immune enhancers is disclosed. A preparation method of the immunotherapeutic pharmaceutical composition, the use of the immune enhancer and the immunotherapeutic pharmaceutical composition are also disclosed. The immune enhancer can be applied to disease and tumor treatments caused by viruses, bacteria, and other microorganisms.

Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by mutant forms of soluble agents that are part of the chimeric proteins. Pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.

Abstract: This invention relates to a surface coating for capture circulating rare cells, comprising a nonfouling composition to prevent the binding of non-specific cells and adsorption of serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the nonfouling and bioactive compositions. The invention also provide a surface coating for capture and purification of a biological substance, comprising a releasable composition to release the non-specific cells and other serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the releasable and bioactive compositions. The present invention also discloses a novel microfluidic chip, with specific patterned microstructures to create a flow disturbance and increase the capture rate of the biological substance.

Abstract: Methods are disclosed for identifying one or more proteins or polypeptides comprised by a sample. The methods comprise determining binding of each polypeptide with respect to each binding pool of a plurality of binding pools, wherein each binding pool comprises one or more probes which bind a structure comprised by a protein or polypeptide. In some aspects, polypeptides can be denatured and separated into individual polypeptide strands and immobilized on a solid support prior to determining binding of the binding pools. A protein, polypeptide or polypeptide strand can be identified by searching, in at least one database, for a protein or polypeptide sequence comprising binding pool targets either identical to or most similar to the binding pool targets comprised by the protein, polypeptide or polypeptide strand to be identified. Kits for identifying proteins, polypeptides and polypeptide strands are also disclosed.

Abstract: This disclosure provides novel anionic amphiphilic ?-hairpin peptides that self-assemble under appropriate conditions to form a reversible gel-sol hydrogel that can be used, for example, to readily deliver protein therapeutics and cells by injection to a target location in a subject.

Abstract: Disclosed is a method for treating an ocular inflammatory disease (OID), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an OID, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway.

Abstract: A method for purifying and enriching mesenchymal stem cells (MSCs) simply and efficiently. Separation of cells expressing CD73 protein on the surface from fresh tissue isolated from a living body allows purification and enrichment of MSCs easily and efficiently. MSCs may be selectively isolated with a single antibody before culturing to establish a culture system of mesenchymal stem cells that enhances the engraftment efficiency in the transplanted site.

Abstract: In one aspect, use of 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG) for treating or preventing acute radiation syndrome is provided.

Abstract: Lesions associated with acute ischemic stroke are automatically segmented in images acquired with computed tomography (“CT”) using a trained machine learning algorithm (e.g., a neural network). The machine learning algorithm is trained on labeled data and associated CT data (e.g., non-contrast CT data and CT angiography source image (“CTA-SI”) data). The labeled data can include segmented data indicating lesions, which are generated by segmenting diffusion-weighted magnetic resonance images acquired within a specified time window from when the associated CT data were acquired. CT data (e.g., non-contrast CT data and CTA-SI data) acquired from a subject are then acquired and input to the trained machine learning algorithm to generate output as segmented CT data, which indicate lesions in the subject.

Abstract: Methods and compositions for treating and alleviating symptoms of irradiation injuries, therapeutic radiation intervention and/or anti-cancer therapies in a subject via pulmonary airway administration of granulocyte macrophage colony stimulating factor (GM-CSF) or a compound with similar affinity to the specific alveolar GM-CSF receptor to enhance pulmonary host defense are provided.

Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

Abstract: An immunoregulatory agent containing a regulatory agent that regulates Dedicator of cytokinesis 2 (DOCK2)-mediated Rac activation as an active ingredient is provided.

Abstract: The present invention relates to new anti-angiopoietin 2 (ANGPT2) neutralizing antibodies for therapeutic and diagnostic methods and composition using them.

Abstract: The present invention relates to methods that use novel biomarkers for diagnosing and/or treating Kawasaki diseases. The novel biomarkers of the invention show altered cytosine methylations state of certain CpG loci in subject with Kawasaki Disease relative to subject without Kawasaki diseases. Also provided are kits comprising at least one primer or reagent specific for the altered cytosine methylation state of certain CpG loci to detect Kawasaki Disease.

Abstract: The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula: wherein an average value of n is 4 or larger and 1136 or smaller.

Abstract: The present invention relates to a method for ex vivo generating and expanding MHCII restricted CD4+ Foxp3+ regulatory T cells, and therapeutic uses thereof. The inventors here demonstrated the optimal conditions for inducing Foxp3 expression in naive CD3+ CD4+ TCR??+ MHCII restricted T following polyclonal or following antigen-specific activation. They also developed an experimental procedure to generate autologous CD8+ T cell lines functionally committed to lyse tumor-antigen specific FOXP3 expressing TCR??+ MHCII restricted T cells, pathogenic CD4+ T cells that favour tumor cell immune evasion. In particular, the present invention relates to a method for generating ex vivo MHCII restricted CD4+ Foxp3+ regulatory T cells having the following phenotype: CD3+ CD4+ Foxp3+.

Abstract: The method for aiding ALS detection provided by the present invention includes determining a profile of signal peptides contained in a bodily fluid from a test subject, and comparing the signal peptide profile thus determined for the test subject with a previously-determined profile of signal peptides in a bodily fluid from a healthy subject. The presence of a difference between the signal peptide profile of the test subject and the signal peptide profile of the healthy subject at a specific molecular weight is then associated with the test subject's suffering from or developing ALS.

Abstract: The present invention relates to a novel protein formulation. In particular, the invention relates to a liquid pharmaceutical composition of tocilizumab, a method of manufacturing the composition, a kit including the composition, a package including the composition and to methods of treatment using the composition and/or package.

Abstract: A device for delivering a predetermined amount of a substance within at least one body cavity of a subject, where the predetermined amount is at an effective amount for treatment of obesity or binge eating disorder. The device includes (a) A volume to contain the predetermined amount of the substance. (b) A delivery end placeable in proximity to the body cavity. The delivery end is in fluid communication with the volume and comprises at least one orifice. (c) A valve mechanically connected to the volume, with at least two configurations: (i) an active configuration configured to deliver the predetermined amount of the substance; and, (ii) an inactive configuration, in which the valve prevents delivery of the predetermined amount of the substance. (d) A fluid tight chamber configured to contain a predetermined volume of pressurized gas at a predetermined pressure.

Abstract: The present invention relates to a method for the preparation of an immunogenic lysate from mesothelioma tumor cells, to such a lysate and to dendritic cells loaded with the lysate, the present invention further relates a pharmaceutical composition comprising such lysate or dendritic cells, to the use of the lysate, and to said loaded dendritic cells or said pharmaceutical composition for use in the prevention or treatment of mesothelioma.

Abstract: The invention relates to medicines, and more particularly to an abortion medication and an administration thereof, where the abortion medication contains 40-60 mg/mL of a kidney bean lectin. The invention also provides another abortion medication, which contains 40-60 mg/mL of a kidney bean lectin, 40-50 mg/mL of an oligosaccharide and 6-9 mg/mL of NaCl. The two abortion medications provided herein are both capable of effectively terminating the pregnancy and are safe without toxic side effects. Moreover, these drugs can be reused several times. These abortion medications are administered intrauterinely, which enables the kidney bean lectin therein to show the best abortive effect, and the local administration of these drugs in the uterine cavity has relatively simple operation.

Abstract: Compositions comprising bis(tryptophan) derivatives are provided that act as antimicrobials. Also provided are methods for reversing antibiotic resistance in a bacterium, or recovering or enhancing antimicrobial activity of an antibiotic against a variety of microbes, by co-administration with a bis(tryptophan) derivative.

Abstract: Compositions and blends of biopolymers and bio-acceptable polymers are described, along with the use of benign solvent systems to prepare biocompatible scaffolds and surgically implantable devices for use in supporting and facilitating the repair of soft tissue injuries.

Abstract: This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences T cell balance, for example, Th17 cell differentiation, maintenance and/or function, as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences T cell balance in a variety of therapeutic and/or diagnostic indications. This invention also relates generally to identifying and exploiting target genes and/or target gene products that modulate, control or otherwise influence T cell balance in a variety of therapeutic and/or diagnostic indications.

Abstract: A method of treating a patient having an elevated inflammatory response, such as an elevated Type I interferon response, is provided. The method can be used to treat sepsis. The method comprises administering to a patient having an elevated inflammatory response, an inhibitor of anaplastic lymphoma kinase (ALK inhibitors) or expression of ALK, in an amount effective to treat the elevated inflammatory response.

Abstract: Compositions and methods for the treatment of Sjogren's syndrome (SS) and SS-related symptoms in human subjects are described. The compositions comprise synthetic peptides based on the sequence of CDR1 of an anti-DNA monoclonal antibody.

Abstract: Described is a composition comprising a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2, and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and an inhibitor of viral neuraminidase.

Abstract: Methods and compositions for generating immune responses using adenovirus vectors that allow multiple vaccinations or in combination with other therapy and vaccinations in individuals with preexisting immunity to adenovirus are provided.

Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Abstract: The object of the present invention is to provide a test method using a novel administration method of an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract. It has been demonstrated that by sustainedly administering an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract by using a continuous administration device according to the present invention, a comparable effect is exerted at a very low dose compared with conventional administration methods such as oral administration. Therefore, the present invention can provide a test method using animals requiring less burden on a researcher, a treatment of patient at a low dose, and the like.

Abstract: This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified ?1-?2 domains of NKG2D ligands. This application further relates to modified ?1-?2 domains of NKG2D ligands attached to polypeptides, in some embodiments antibodies or fragments of antibodies. This application further relates to antigen-binding peptides derived from light and heavy chain antibody variable domains, which contain two linker regions and a split variable domain.

Abstract: Compositions and methods are provided for treating companion animals are provided. An adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding erythropoietin (EPO). In desired embodiments, the subject is a cat or dog.

Abstract: The present invention concerns a solid, palatable composition and its preparation process which, relative to the total weight of the composition, comprises: 5 to 30%, preferably 8 to 20% by weight of at least one fat chosen from among a liquid oil, a fat, wax or mixture thereof, the liquid oil not to represent more than 8% by weight of the composition; 0.001 to 85% by weight of at least one active substance; and 20 to 95%, preferably 40 to 70% by weight of at least one palatable material, for use thereof as medicinal product, nutraceutical or food supplement, for oral administration to mammals, except man, in particular for domestic animals such as dogs, cats or horses. The said solid composition is obtained by mixing the components, vaporising the fats, calibrating the dry, fluid granular material and compressing the granular material in a stock cube press.

Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.

Abstract: The present disclosure provides for and relates to cancer treatment based on the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.

Abstract: The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

Abstract: A method for detecting and typing rare tumor cells having high metabolic activity in a body fluid sample, comprising the following steps: incubating nucleated cells in a body fluid sample with a first metabolic marker and a second metabolic marker capable of producing fluorescence signals; detecting, by means of high-throughput imaging, uptake of all the fluorescence signals of the metabolic markers by cells, so as to determine the energy metabolism mode and intensity of the cells; and identifying and typing, according to the fluorescence signals of the metabolic marker combination, tumor cells having high metabolic activity in the body fluid sample. Further provided is a kit used for the detecting and typing method, comprising a microwell array chip, a first metabolic marker and a second metabolic marker capable of producing fluorescence signals, and fluorescence-labeled antibodies specific to leukocyte common antigen.

Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: A three-dimensional fibrin engineered tissue construct is provided selected from: (i) a fibrin gel matrix comprising a combination of tissue-specific cells and at least one type of vascular cells; and (ii) a hybrid scaffold of fibrin gel and a polymeric synthetic scaffold comprising at least one type of vascular cells or a combination of tissue-specific cells and at least one type of vascular cells.

Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.

Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.

Abstract: The present invention relates to methods for the preparation of compositions comprising adipose tissue-derived secretions, for example those derived from bovine adipose tissue, and the use of such compositions in the preparation of a pharmaceutical composition for topical use. The invention also relates to the use of adipose tissue-derived secretions and pharmaceutical compositions thereof for the topical treatment of a non-inflammatory condition, for example the treatment of a skin condition, and for the stimulation of hair growth in a subject by topical application. The invention also relates to the use of adipose tissue-derived secretions and pharmaceutical compositions thereof for the topical treatment of acne.

Abstract: NK cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Production of modified NK cells and NK cell lines is via genetic modification to remove checkpoint inhibitory receptor expression and/or add mutant (variant) TRAIL ligand expression.

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGF? trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

Abstract: Disclosed is a CD154 binding polypeptide that specifically recognizes CD154. The polypeptide according to the present disclosure effectively inhibits the CD154-CD40 interaction without activating platelets, and thus can be effectively used in the prevention or treatment of various T cell-mediated or antibody-mediated diseases or symptoms, which requires inhibition of the interaction.

Abstract: The invention relates to transduction compounds, buffers and methods for introducing molecules into cells. The invention also relates to methods of treatment, pharmaceutical compositions and other uses of the transduction compounds and buffers. The invention also relates to modified cells obtainable by the transduction compounds, buffers and methods of the invention.

Abstract: Engineered orthogonal cytokine receptor/ligand pairs, and methods of use thereof, are provided.

Abstract: Certain embodiments are directed to novel heterotrimeric fusions in which the ectodomain of the TGF-? type II receptor (T?P?II) is coupled to the N- and C-terminal ends of the endoglin-domain of the TGF-? type III receptor (TpRIIIE). Certain embodiments are directed to novel heterotrimeric polypeptides in which the ectodomain of the TGF-? type II receptor (TI3RII) is coupled to the N- and C-terminal ends of the endoglin-domain (E domain) of the TGF-? type III receptor (TI3RIII). This trimeric receptor, known as RER, can bind all three TGF-? isoforms with sub-nanomolar affinity and is effective at neutralizing signaling induced by all three TGF-? isoforms, but not other ligands of the TGF-? superfamily, such as activins, growth and differentiation factors (GDFs), and bone morphonogenetic proteins (BMPs).